A detailed history of Aimz Investment Advisors, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Aimz Investment Advisors, LLC holds 39,585 shares of MYGN stock, worth $869,286. This represents 0.35% of its overall portfolio holdings.

Number of Shares
39,585
Previous 39,585 -0.0%
Holding current value
$869,286
Previous $843,000 14.83%
% of portfolio
0.35%
Previous 0.32%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$17.59 - $23.59 $21,108 - $28,308
-1,200 Reduced 2.94%
39,585 $843,000
Q4 2023

Jan 26, 2024

SELL
$13.91 - $21.32 $2,782 - $4,264
-200 Reduced 0.49%
40,785 $780,000
Q3 2023

Nov 13, 2023

SELL
$15.99 - $23.22 $11,193 - $16,254
-700 Reduced 1.68%
40,985 $657,000
Q4 2022

Feb 10, 2023

SELL
$14.51 - $20.99 $5,804 - $8,396
-400 Reduced 0.95%
41,685 $605,000
Q2 2022

Aug 02, 2022

SELL
$16.45 - $25.88 $9,870 - $15,528
-600 Reduced 1.41%
42,085 $765,000
Q1 2022

May 06, 2022

SELL
$22.67 - $28.01 $34,005 - $42,015
-1,500 Reduced 3.39%
42,685 $1.08 Million
Q4 2021

Feb 09, 2022

BUY
$24.13 - $32.63 $36,195 - $48,945
1,500 Added 3.51%
44,185 $1.22 Million
Q2 2020

Aug 07, 2020

SELL
$10.69 - $16.49 $2,138 - $3,297
-200 Reduced 0.47%
42,685 $484,000
Q4 2019

Feb 13, 2020

SELL
$20.93 - $35.1 $12,558 - $21,060
-600 Reduced 1.38%
42,885 $1.17 Million
Q3 2018

Nov 13, 2018

SELL
$37.57 - $50.34 $18,785 - $25,170
-500 Reduced 1.14%
43,485 $2 Million
Q2 2018

Aug 14, 2018

BUY
$27.75 - $40.17 $5,550 - $8,034
200 Added 0.46%
43,985 $1.64 Million
Q4 2017

Feb 14, 2018

SELL
$28.45 - $37.14 $2,845 - $3,714
-100 Reduced 0.23%
43,785 $1.5 Million
Q2 2017

Aug 15, 2017

BUY
N/A
43,885
43,885 $1.13 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.77B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Aimz Investment Advisors, LLC Portfolio

Follow Aimz Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aimz Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aimz Investment Advisors, LLC with notifications on news.